These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29102463)

  • 1. Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation.
    Stama ML; Ślusarczyk J; Lacivita E; Kirpotina LN; Schepetkin IA; Chamera K; Riganti C; Perrone R; Quinn MT; Basta-Kaim A; Leopoldo M
    Eur J Med Chem; 2017 Dec; 141():703-720. PubMed ID: 29102463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Ureidopropanamides as Formyl Peptide Receptor 2 (FPR2) Agonists to Target the Resolution of Inflammation in Central Nervous System Disorders.
    Mastromarino M; Favia M; Schepetkin IA; Kirpotina LN; Trojan E; Niso M; Carrieri A; Leśkiewicz M; Regulska M; Darida M; Rossignolo F; Fontana S; Quinn MT; Basta-Kaim A; Leopoldo M; Lacivita E
    J Med Chem; 2022 Mar; 65(6):5004-5028. PubMed ID: 35257581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.
    Schepetkin IA; Kirpotina LN; Khlebnikov AI; Leopoldo M; Lucente E; Lacivita E; De Giorgio P; Quinn MT
    Biochem Pharmacol; 2013 Feb; 85(3):404-16. PubMed ID: 23219934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-Dependent Protective and Pro-Resolving Effects of FPR2 Agonists on Lipopolysaccharide-Exposed Microglia Cells Involve Inhibition of NF-κB and MAPKs Pathways.
    Tylek K; Trojan E; Leśkiewicz M; Regulska M; Bryniarska N; Curzytek K; Lacivita E; Leopoldo M; Basta-Kaim A
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional N-Formyl Peptide Receptor 2 (FPR2) Antagonists Based on the Ureidopropanamide Scaffold Have Potential To Protect Against Inflammation-Associated Oxidative Stress.
    Stama ML; Lacivita E; Kirpotina LN; Niso M; Perrone R; Schepetkin IA; Quinn MT; Leopoldo M
    ChemMedChem; 2017 Nov; 12(22):1839-1847. PubMed ID: 28922577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of novel cyclopentane urea FPR2 agonists and their potential application in the treatment of cardiovascular inflammation.
    Maciuszek M; Ortega-Gomez A; Maas SL; Perretti M; Merritt A; Soehnlein O; Chapman TM
    Eur J Med Chem; 2021 Mar; 214():113194. PubMed ID: 33548634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functions of resolvin D1-ALX/FPR2 receptor interaction in the hemoglobin-induced microglial inflammatory response and neuronal injury.
    Liu GJ; Tao T; Wang H; Zhou Y; Gao X; Gao YY; Hang CH; Li W
    J Neuroinflammation; 2020 Aug; 17(1):239. PubMed ID: 32795323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2.
    Lacivita E; Schepetkin IA; Stama ML; Kirpotina LN; Colabufo NA; Perrone R; Khlebnikov AI; Quinn MT; Leopoldo M
    Bioorg Med Chem; 2015 Jul; 23(14):3913-24. PubMed ID: 25549897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A
    de Gaetano M; Tighe C; Gahan K; Zanetti A; Chen J; Newson J; Cacace A; Marai M; Gaffney A; Brennan E; Kantharidis P; Cooper ME; Leroy X; Perretti M; Gilroy D; Godson C; Guiry PJ
    J Med Chem; 2021 Jul; 64(13):9193-9216. PubMed ID: 34138563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microglia Depletion Attenuates the Pro-Resolving Activity of the Formyl Peptide Receptor 2 Agonist AMS21 Related to Inhibition of Inflammasome NLRP3 Signalling Pathway: A Study of Organotypic Hippocampal Cultures.
    Tylek K; Trojan E; Leśkiewicz M; Ghafir El Idrissi I; Lacivita E; Leopoldo M; Basta-Kaim A
    Cells; 2023 Nov; 12(21):. PubMed ID: 37947648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoxin A4 Reduces Inflammation Through Formyl Peptide Receptor 2/p38 MAPK Signaling Pathway in Subarachnoid Hemorrhage Rats.
    Guo Z; Hu Q; Xu L; Guo ZN; Ou Y; He Y; Yin C; Sun X; Tang J; Zhang JH
    Stroke; 2016 Feb; 47(2):490-7. PubMed ID: 26732571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential.
    Maciuszek M; Cacace A; Brennan E; Godson C; Chapman TM
    Eur J Med Chem; 2021 Mar; 213():113167. PubMed ID: 33486199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of a series of non-steroidal anti-inflammatory drug conjugates as novel neuroinflammatory inhibitors.
    Xu Z; Wu J; Zheng J; Ma H; Zhang H; Zhen X; Zheng LT; Zhang X
    Int Immunopharmacol; 2015 Apr; 25(2):528-37. PubMed ID: 25765352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of novel pyrrolidinone small-molecule Formyl peptide receptor 2 agonists.
    Maciuszek M; Ortega-Gomez A; Maas SL; Garrido-Mesa J; Ferraro B; Perretti M; Merritt A; Nicolaes GAF; Soehnlein O; Chapman TM
    Eur J Med Chem; 2021 Dec; 226():113805. PubMed ID: 34536667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RvD1binding with FPR2 attenuates inflammation via Rac1/NOX2 pathway after neonatal hypoxic-ischemic injury in rats.
    Liu W; Huang J; Doycheva D; Gamdzyk M; Tang J; Zhang JH
    Exp Neurol; 2019 Oct; 320():112982. PubMed ID: 31247196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial lipopolysaccharide selectively up-regulates the function of the chemotactic peptide receptor formyl peptide receptor 2 in murine microglial cells.
    Cui YH; Le Y; Gong W; Proost P; Van Damme J; Murphy WJ; Wang JM
    J Immunol; 2002 Jan; 168(1):434-42. PubMed ID: 11751990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The N-Formyl Peptide Receptor 2 (FPR2) Agonist MR-39 Exhibits Anti-Inflammatory Activity in LPS-Stimulated Organotypic Hippocampal Cultures.
    Trojan E; Tylek K; Leśkiewicz M; Lasoń W; Brandenburg LO; Leopoldo M; Lacivita E; Basta-Kaim A
    Cells; 2021 Jun; 10(6):. PubMed ID: 34204273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Lipidated Peptidomimetic Lau-((S)-Aoc)-(Lys-βNphe)6-NH2 Is a Novel Formyl Peptide Receptor 2 Agonist That Activates Both Human and Mouse Neutrophil NADPH Oxidase.
    Holdfeldt A; Skovbakke SL; Winther M; Gabl M; Nielsen C; Perez-Gassol I; Larsen CJ; Wang JM; Karlsson A; Dahlgren C; Forsman H; Franzyk H
    J Biol Chem; 2016 Sep; 291(38):19888-99. PubMed ID: 27422818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.
    Schepetkin IA; Kirpotina LN; Khlebnikov AI; Jutila MA; Quinn MT
    Mol Pharmacol; 2011 Jan; 79(1):77-90. PubMed ID: 20943772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-neuroinflammatory effects of DPTP, a novel synthetic clovamide derivative in in vitro and in vivo model of neuroinflammation.
    Lim HW; Park JI; More SV; Park JY; Kim BW; Jeon SB; Yun YS; Park EJ; Yoon SH; Choi DK
    Brain Res Bull; 2015 Mar; 112():25-34. PubMed ID: 25596423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.